Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: Radiation oncology report of the Department of Defense Center for Prostate Disease Research

Peter A S Johnstone, Christopher J. Kane, Leon Sun, Hongyu Wu, Judd W. Moul, David G. McLeod, Douglas D. Martin, Leo Kusuda, Raymond Lance, Robert Douglas, Timothy Donahue, Michael G. Beat, John Foley, Dalton Baldwin, Douglas Soderdahl, Jason Do, Christopher Amling

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

PURPOSE: To report on the first collaboration of the Department of Defense Center for Prostate Disease Research concerned with the relationship between African American race and biochemical disease-free outcomes after definitive radiation therapy. MATERIALS AND METHODS: Information from the medical records of 1,806 patients (1,349 white, 343 African American, 42 of "other" races, and 72 of "unknown" races) treated with definitive radiation therapy between 1973 and 2000 was reviewed. Patients receiving adjuvant hormonal therapy or postoperative adjuvant or salvage radiation therapy were excluded. Biochemical failure was calculated in over 96% of cases by using ASTRO criteria; patients with fewer than three follow-up visits were considered to have biochemical failure with a prostate-specific antigen (PSA) value more than 10-fold the previous value or with any value greater than 50.0 ng/mL. Median radiation therapy doses were similar. The median follow-up was 58.4 months. Kaplan-Meier tests, Cox proportional hazards regression analysis, and log-rank tests were used for data analysis. RESULTS: There was no statistically significant difference in biochemical disease-free survival according to race when patients were stratified according to T stage. African American race conferred a negative prognosis for patients with lesions of Gleason biopsy score 7 (P = .004) but not for patients with lesions of Gleason score 2-4 (P = .14), 5-6 (P = .79), or 8-10 (P = .86). Similarly, African American race conferred a negative prognosis in patients with PSA values of 20.1-50.0 ng/mL (P = .01) at presentation but not in patients with PSA values less than or equal to 4.0 ng/mL (P = .84), 4.1 -10.0 ng/mL (P = .71), 10.1-20.0 ng/mL (P = .75), or above 50.0 ng/mL (P = .15) at presentation. At multivariate analysis, race was not a statistically significant predictor of outcome. CONCLUSION: In the equal-access health care system of the Department of Defense, African American race is not associated with a consistently negative prognosis in patients treated with definitive radiation therapy for prostate cancer. Race appears to confer a negative prognosis only in patients with advanced disease at presentation.

Original languageEnglish (US)
Pages (from-to)420-426
Number of pages7
JournalRadiology
Volume225
Issue number2
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Radiation Oncology
Prostate
Prostatic Neoplasms
Radiotherapy
Delivery of Health Care
Research
African Americans
Prostate-Specific Antigen
Neoplasm Grading
Salvage Therapy
Kaplan-Meier Estimate
Disease-Free Survival
Medical Records
Multivariate Analysis
Regression Analysis
Biopsy

Keywords

  • Data analysis
  • Prostate neoplasms
  • Prostate neoplasms, therapeutic radiology

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system : Radiation oncology report of the Department of Defense Center for Prostate Disease Research. / Johnstone, Peter A S; Kane, Christopher J.; Sun, Leon; Wu, Hongyu; Moul, Judd W.; McLeod, David G.; Martin, Douglas D.; Kusuda, Leo; Lance, Raymond; Douglas, Robert; Donahue, Timothy; Beat, Michael G.; Foley, John; Baldwin, Dalton; Soderdahl, Douglas; Do, Jason; Amling, Christopher.

In: Radiology, Vol. 225, No. 2, 01.11.2002, p. 420-426.

Research output: Contribution to journalArticle

Johnstone, PAS, Kane, CJ, Sun, L, Wu, H, Moul, JW, McLeod, DG, Martin, DD, Kusuda, L, Lance, R, Douglas, R, Donahue, T, Beat, MG, Foley, J, Baldwin, D, Soderdahl, D, Do, J & Amling, C 2002, 'Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: Radiation oncology report of the Department of Defense Center for Prostate Disease Research', Radiology, vol. 225, no. 2, pp. 420-426.
Johnstone, Peter A S ; Kane, Christopher J. ; Sun, Leon ; Wu, Hongyu ; Moul, Judd W. ; McLeod, David G. ; Martin, Douglas D. ; Kusuda, Leo ; Lance, Raymond ; Douglas, Robert ; Donahue, Timothy ; Beat, Michael G. ; Foley, John ; Baldwin, Dalton ; Soderdahl, Douglas ; Do, Jason ; Amling, Christopher. / Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system : Radiation oncology report of the Department of Defense Center for Prostate Disease Research. In: Radiology. 2002 ; Vol. 225, No. 2. pp. 420-426.
@article{a6053eae43ee4105bf6768fa82c4f8ac,
title = "Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: Radiation oncology report of the Department of Defense Center for Prostate Disease Research",
abstract = "PURPOSE: To report on the first collaboration of the Department of Defense Center for Prostate Disease Research concerned with the relationship between African American race and biochemical disease-free outcomes after definitive radiation therapy. MATERIALS AND METHODS: Information from the medical records of 1,806 patients (1,349 white, 343 African American, 42 of {"}other{"} races, and 72 of {"}unknown{"} races) treated with definitive radiation therapy between 1973 and 2000 was reviewed. Patients receiving adjuvant hormonal therapy or postoperative adjuvant or salvage radiation therapy were excluded. Biochemical failure was calculated in over 96{\%} of cases by using ASTRO criteria; patients with fewer than three follow-up visits were considered to have biochemical failure with a prostate-specific antigen (PSA) value more than 10-fold the previous value or with any value greater than 50.0 ng/mL. Median radiation therapy doses were similar. The median follow-up was 58.4 months. Kaplan-Meier tests, Cox proportional hazards regression analysis, and log-rank tests were used for data analysis. RESULTS: There was no statistically significant difference in biochemical disease-free survival according to race when patients were stratified according to T stage. African American race conferred a negative prognosis for patients with lesions of Gleason biopsy score 7 (P = .004) but not for patients with lesions of Gleason score 2-4 (P = .14), 5-6 (P = .79), or 8-10 (P = .86). Similarly, African American race conferred a negative prognosis in patients with PSA values of 20.1-50.0 ng/mL (P = .01) at presentation but not in patients with PSA values less than or equal to 4.0 ng/mL (P = .84), 4.1 -10.0 ng/mL (P = .71), 10.1-20.0 ng/mL (P = .75), or above 50.0 ng/mL (P = .15) at presentation. At multivariate analysis, race was not a statistically significant predictor of outcome. CONCLUSION: In the equal-access health care system of the Department of Defense, African American race is not associated with a consistently negative prognosis in patients treated with definitive radiation therapy for prostate cancer. Race appears to confer a negative prognosis only in patients with advanced disease at presentation.",
keywords = "Data analysis, Prostate neoplasms, Prostate neoplasms, therapeutic radiology",
author = "Johnstone, {Peter A S} and Kane, {Christopher J.} and Leon Sun and Hongyu Wu and Moul, {Judd W.} and McLeod, {David G.} and Martin, {Douglas D.} and Leo Kusuda and Raymond Lance and Robert Douglas and Timothy Donahue and Beat, {Michael G.} and John Foley and Dalton Baldwin and Douglas Soderdahl and Jason Do and Christopher Amling",
year = "2002",
month = "11",
day = "1",
language = "English (US)",
volume = "225",
pages = "420--426",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system

T2 - Radiation oncology report of the Department of Defense Center for Prostate Disease Research

AU - Johnstone, Peter A S

AU - Kane, Christopher J.

AU - Sun, Leon

AU - Wu, Hongyu

AU - Moul, Judd W.

AU - McLeod, David G.

AU - Martin, Douglas D.

AU - Kusuda, Leo

AU - Lance, Raymond

AU - Douglas, Robert

AU - Donahue, Timothy

AU - Beat, Michael G.

AU - Foley, John

AU - Baldwin, Dalton

AU - Soderdahl, Douglas

AU - Do, Jason

AU - Amling, Christopher

PY - 2002/11/1

Y1 - 2002/11/1

N2 - PURPOSE: To report on the first collaboration of the Department of Defense Center for Prostate Disease Research concerned with the relationship between African American race and biochemical disease-free outcomes after definitive radiation therapy. MATERIALS AND METHODS: Information from the medical records of 1,806 patients (1,349 white, 343 African American, 42 of "other" races, and 72 of "unknown" races) treated with definitive radiation therapy between 1973 and 2000 was reviewed. Patients receiving adjuvant hormonal therapy or postoperative adjuvant or salvage radiation therapy were excluded. Biochemical failure was calculated in over 96% of cases by using ASTRO criteria; patients with fewer than three follow-up visits were considered to have biochemical failure with a prostate-specific antigen (PSA) value more than 10-fold the previous value or with any value greater than 50.0 ng/mL. Median radiation therapy doses were similar. The median follow-up was 58.4 months. Kaplan-Meier tests, Cox proportional hazards regression analysis, and log-rank tests were used for data analysis. RESULTS: There was no statistically significant difference in biochemical disease-free survival according to race when patients were stratified according to T stage. African American race conferred a negative prognosis for patients with lesions of Gleason biopsy score 7 (P = .004) but not for patients with lesions of Gleason score 2-4 (P = .14), 5-6 (P = .79), or 8-10 (P = .86). Similarly, African American race conferred a negative prognosis in patients with PSA values of 20.1-50.0 ng/mL (P = .01) at presentation but not in patients with PSA values less than or equal to 4.0 ng/mL (P = .84), 4.1 -10.0 ng/mL (P = .71), 10.1-20.0 ng/mL (P = .75), or above 50.0 ng/mL (P = .15) at presentation. At multivariate analysis, race was not a statistically significant predictor of outcome. CONCLUSION: In the equal-access health care system of the Department of Defense, African American race is not associated with a consistently negative prognosis in patients treated with definitive radiation therapy for prostate cancer. Race appears to confer a negative prognosis only in patients with advanced disease at presentation.

AB - PURPOSE: To report on the first collaboration of the Department of Defense Center for Prostate Disease Research concerned with the relationship between African American race and biochemical disease-free outcomes after definitive radiation therapy. MATERIALS AND METHODS: Information from the medical records of 1,806 patients (1,349 white, 343 African American, 42 of "other" races, and 72 of "unknown" races) treated with definitive radiation therapy between 1973 and 2000 was reviewed. Patients receiving adjuvant hormonal therapy or postoperative adjuvant or salvage radiation therapy were excluded. Biochemical failure was calculated in over 96% of cases by using ASTRO criteria; patients with fewer than three follow-up visits were considered to have biochemical failure with a prostate-specific antigen (PSA) value more than 10-fold the previous value or with any value greater than 50.0 ng/mL. Median radiation therapy doses were similar. The median follow-up was 58.4 months. Kaplan-Meier tests, Cox proportional hazards regression analysis, and log-rank tests were used for data analysis. RESULTS: There was no statistically significant difference in biochemical disease-free survival according to race when patients were stratified according to T stage. African American race conferred a negative prognosis for patients with lesions of Gleason biopsy score 7 (P = .004) but not for patients with lesions of Gleason score 2-4 (P = .14), 5-6 (P = .79), or 8-10 (P = .86). Similarly, African American race conferred a negative prognosis in patients with PSA values of 20.1-50.0 ng/mL (P = .01) at presentation but not in patients with PSA values less than or equal to 4.0 ng/mL (P = .84), 4.1 -10.0 ng/mL (P = .71), 10.1-20.0 ng/mL (P = .75), or above 50.0 ng/mL (P = .15) at presentation. At multivariate analysis, race was not a statistically significant predictor of outcome. CONCLUSION: In the equal-access health care system of the Department of Defense, African American race is not associated with a consistently negative prognosis in patients treated with definitive radiation therapy for prostate cancer. Race appears to confer a negative prognosis only in patients with advanced disease at presentation.

KW - Data analysis

KW - Prostate neoplasms

KW - Prostate neoplasms, therapeutic radiology

UR - http://www.scopus.com/inward/record.url?scp=0036829399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036829399&partnerID=8YFLogxK

M3 - Article

C2 - 12409575

AN - SCOPUS:0036829399

VL - 225

SP - 420

EP - 426

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -